Peter Schmidt

Witten/Herdecke University — Germany

Arts and Humanities · Social Sciences

22h-index2.2kcitations204works4.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

German Literature and Culture Studies(15), Anesthesia and Pain Management(14), SARS-CoV-2 and COVID-19 Research(13), COVID-19 Clinical Research Studies(10), Migraine and Headache Studies(9)

Publications204 total

PORT-77 is a potent inhibitor of ABCG2 that reduces efflux of protoporphyrin IX from erythrocytes of patients with protoporphyria and reduces plasma protoporphyrin IX levels in healthy human subjects
Blood·2025Open Access
S3-Leitlinie „Seltene Erkrankungen der Zähne“
Oralprophylaxe & Kinderzahnmedizin·2025
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From a Phase 3 Randomized Clinical Trial (CANOPY)
Clinical Infectious Diseases·2025· 8 citedOpen Access
Tooth brushing behavior and oral health care of people with early childhood autism in Germany
Clinical Oral Investigations·2025· 4 citedOpen Access
Dental Management of Genetic Dental Disorders: A Critical Review
Journal of Dental Research·2025· 5 citedOpen Access
Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial
2024· 4 citedOpen Access
Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19
New England Journal of Medicine·2024· 21 citedOpen Access
PORT-77, a Novel and Potent Inhibitor of ABCG2, Protects Against Skin Photo Toxicity and Liver Damage in a Mouse Model of Erythropoietic Protoporphyria (EPP)
Blood·2024Open Access
Orthodontic findings and treatment need in patients with amelogenesis imperfecta: a descriptive analysis
Head & Face Medicine·2024· 4 citedOpen Access
Supplementing Best Care with Specialized Rehabilitation Treatment in Parkinson’s Disease: A Retrospective Study by Different Expert Centers
Journal of Clinical Medicine·2024· 1 citedOpen Access
1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention
Open Forum Infectious Diseases·2023· 2 citedOpen Access
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Open Forum Infectious Diseases·2023· 22 citedOpen Access
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Open Forum Infectious Diseases·2023· 13 citedOpen Access
Orofacial findings and orthodontic treatment conditions in patients with down syndrome – a retrospective investigation
Head & Face Medicine·2023· 10 citedOpen Access
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Infectious Diseases and Therapy·2023· 7 citedOpen Access
48. Depression and the Menopausal Transition: A Prospective Longitudinal Study
Biological Psychiatry·2023
23. Longitudinal Characterization of White Matter Myelination in Vivo in the Healthy Human Brain a From Childhood to Adulthood
Biological Psychiatry·2023
Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers
Science Translational Medicine·2023· 38 citedOpen Access
591. Adintrevimab (ADI) Population Pharmacokinetics (PPK) in Phase 1 and Phase 2/3 COVID-19 Prevention and Treatment Study Participants
Open Forum Infectious Diseases·2022· 1 citedOpen Access
226. Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study
Open Forum Infectious Diseases·2022Open Access
page 1 of 11Next →

Frequent Co-authors

Marc Moritz Berger(10), Mahdi Sareban(10), Josef Niebauer(9), Franziska Macholz(8), Heimo Mairbäurl(6), Sean Mackey(5), Ian Carroll(5), Donald Kellerman(5), Sebastian Fried(5), Lisa Maria Schiefer(5), Jennifer M. Hah(4), Rebecca McCue(4), Jodie Trafton(4), Gabriela Ruchelli(4), Stuart B. Goodman(4), Kristin Narayan(4), Peter Bärtsch(4), Tabea Perz(4), Bernhard Reich(4), Debra Clay(3)